SCHEMBL12412401

SCHEMBL12412401

COc1c(C)cc(Cl)cc1C(C)C

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.47
GABRB1 P18505 1/20 0.47
SCN4A P35499 4/20 0.43
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
GFER P55789 1/20 0.38
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ATM Q13315 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
AKR1B1 P15121 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12974084 0.82 GABRA1 (0.48) GABRA1GABRB1GAALMNASMN1; SMN2
SCHEMBL12504651 0.80 SCN4A (0.44) SCN4APOLBLMNASMN1; SMN2MAPT
SCHEMBL15219673 0.80 GABRA1 (0.47) GABRA1GABRB1POLBGAAGFER
SCHEMBL17658897 0.78 GABRA1 (0.45) GABRA1GABRB1POLBGAAGFER
SCHEMBL19122089 0.78 GABRA1 (0.45) GABRA1GABRB1POLBGAAGFER
SCHEMBL10499136 0.75 TSHR (0.39) SCN4AGAA
SCHEMBL10500124 0.75 SCN4A (0.34) GABRA1GABRB1SCN4ALMNASMN1; SMN2
SCHEMBL13706379 0.74 CA1 (0.39) POLBGAAGFERLMNA
SCHEMBL13843683 0.74 POLB (0.38) POLBGAAGFER
SCHEMBL10499621 0.74 TAS1R3 (0.39) SCN4AGAALMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170283397-A1 SUBSTITUTED 1-H-INDOL-3-YL-BENZAMIDE AND 1, 1'-BIPHENYL ANALOGS AS HISTONE DEMETHYLASE INHIBITORS UNIV UTAH RES FOUND (US) 2017-10-05 US disclosed
US-20170283397-A1 SUBSTITUTED 1-H-INDOL-3-YL-BENZAMIDE AND 1, 1'-BIPHENYL ANALOGS AS HISTONE DEMETHYLASE INHIBITORS UNIV UTAH RES FOUND (US) 2017-10-05 US disclosed
US-8962244-B2 Compounds for modulating RNA binding proteins and uses therefor UNIVERSITY OF MASSACHUSETTS (US) 2015-02-24 US disclosed
US-20130217685-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR UNIVERSITY OF MASSACHUSETTS (US) 2013-08-22 US disclosed
US-8440706-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-14 US disclosed
US-8377639-B2 Compounds for modulating RNA binding proteins and uses therefor UNIVERSITY OF MASSACHUSETTS (US) 2013-02-19 US disclosed
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-07 US disclosed
US-20110065704-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217685-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR TIA1, ZFP3, RBM3 GABRA1 1857/4885GABRB1 1729/4885SCN4A 3714/4885
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES PRSS1, PRSS3, PRSS2 GABRA1 4356/4885GABRB1 4309/4885SCN4A 309/4885
US-20170283397-A1 SUBSTITUTED 1-H-INDOL-3-YL-BENZAMIDE AND 1, 1'-BIPHENYL ANALOGS AS HISTONE DEMETHYLASE INHIBITORS KDM1A, KDM1B, KDM3A GABRA1 532/4885GABRB1 297/4885SCN4A 2852/4885
US-20110065704-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR TIA1, ZFP3, RBM3 GABRA1 1857/4885GABRB1 1729/4885SCN4A 3714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.